-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

887 Efficacy and Safety of Tinzaparin in CAT Patients with Metastatic Disease

Program: Oral and Poster Abstracts
Session: 332. Anticoagulation and Antithrombotic Therapy: Poster I
Hematology Disease Topics & Pathways:
anticoagulant drugs, Diseases, Bleeding and Clotting, Non-Biological, Therapies, Thrombosis
Saturday, December 5, 2020, 7:00 AM-3:30 PM

Agnes Y. Lee, MD, MSc1, Pieter W. Kamphuisen, MD, PhD2*, Rupert Bauersachs, MD, PhD3,4*, Karen Turpin, BScN, MSc5*, Jes Birger Hansen6* and Alok A Khorana, MD7

1Department of Hematology, University of British Columbia, Vancouver, BC, Canada
2University Medical Center Groningen, Groningen, NLD
3Department Vascular Medicine, Darmstadt Hospital, Darmstadt, DEU
4Center of Thrombosis and Haemostasis, University of Mainz, Mainz, Germany
5Medical Affairs, Leo Pharma Canada, Thornhill, ON, Canada
6LEO Pharma A/S, Ballerup, France
7Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH


Venous thromboembolism (VTE) frequently complicates the course of active cancer with a significant impact on morbidity and mortality. The results of CATCH trial for treatment of cancer-associated thrombosis (CAT) have been reported and included patients with and without metastatic disease. As metastatic disease is known to be associated with a higher risk of recurrent VTE and bleeding, we performed these post hoc analyses to assess the recurrent VTE (rVTE), recurrent deep vein thrombosis (rDVT), and bleeding events (major bleeding (MB), clinically relevant (CRB) and clinically relevant non-major (CRNMB)) in patients with CAT with metastatic disease. Risk factors associated with rVTE, rDVT and CRB were also explored.


CATCH (ClinicalTrials.govNCT01130025; Lee A et al. JAMA 2015) was a Phase III, multinational, randomized, active-controlled, open-label trial. Patients with solid tumor cancer and haematological malignancies were included. Patients were randomized to receive therapeutic dosing of tinzaparin (175 U/kg OD) vs warfarin (INR target 2.0 – 3.0). Treatment was given for up to 6 months. The primary efficacy outcome was the composite of symptomatic DVT, symptomatic nonfatal pulmonary embolism (PE), fatal PE, incidental proximal DVT and incidental proximal PE. All cumulative incidence VTE and MB outcome were objectively documented and centrally adjudicated in a treatment-blinded fashion. Patients who had known metastatic solid tumor at presentation were included in these analysis. The regression model compared the two treatment groups adjusting for competing risks and geographical region and history of VTE.


Among the CATCH study population, 55% had metastatic disease. Of these patients, 247 and 245 received tinzaparin and warfarin, respectively, with no significant differences in patient characteristics between treatment groups. Patients with metastatic disease had a higher incidence of rVTE (10.2% vs 7.0%) and symptomatic non-fatal rDVT (5.5% vs 2.9%) compared to patients without metastatic disease. Patients with metastatic disease also had a higher incidence of MB (2.8% vs 1.9%), CRB (17.7%% vs 11.8%) and CRNMB (15.0% vs 10.5%) compared to patients without metastatic disease. rVTE occurred in significantly fewer patients assigned to tinzaparin (6.8%) versus warfarin (14.4%) (HR 0.45; 95%CI 0.25-0.80; p=0.007). rDVT also occurred significantly less frequently in patients assigned to tinzaparin (3.0%) versus warfarin (8.4%) (HR 0.34; 95%CI 0.15-0.81; p=0.015). 96% of rVTE were symptomatic. There was no significant difference in MB between tinzaparin- and warfarin-treated patients (4.0% vs 1.6%; HR 2.17; 95%CI 0.71-6.65; p=0.177), but tinzaparin was associated with significantly lower risk of CRB (15.8% vs 19.6%; HR 0.63; 95%CI 0.41-0.97; p=0.037) and CRNMB (12.1% vs 18.0%; HR 0.53; 95%CI 0.33-0.84; p=0.008). Factors associated with rVTE in patients with metastatic disease included central venous catheterization (HR 0.10; 95%CI 0.01-0.79; p=0.029), venous compression from mass or adenopathy (HR 3.99; 95%CI 2.14-7.43; p<0.001), and hepatobiliary cancer (HR 4.07; 95%CI 1.65-10.0; p=0.002). The latter two were also significant risk factors for rDVT. Age > 75 (HR 2.56; 95%CI 1.43-4.60; p=0.002) and known intracranial pathology (HR 2.24; 95%CI 1.07-4.66; p=0.031) were found to be significant risk factors for CRB.


CAT patients with metastatic diseases have higher risks of rVTE and bleeding compared with patients without metastases. Amongst CAT patients with metastatic solid tumors, treatment with tinzaparin was associated with significantly lower risk of rVTE and rDVT and significantly lower risk of CRB and CRNMB compared with warfarin. Tinzaparin offers a favourable risk-benefit profile in treatment of CAT in patients with metastatic solid tumors.

Disclosures: Lee: Pfizer: Consultancy, Honoraria; BMS: Research Funding; LEO Pharma A/S: Consultancy, Honoraria; Bayer: Consultancy, Honoraria, Other: Advisory board, steering committee. Bauersachs: Pfizer: Consultancy, Honoraria; LEO Pharma A/S: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Bayer: Consultancy, Honoraria; Aspen: Consultancy, Honoraria. Turpin: LEO Pharma Canada: Current Employment. Hansen: LEO Pharma A/S: Current Employment. Khorana: Leo Pharma: Honoraria; Merck: Research Funding; Array: Other: Research funding (to institution); Leap: Research Funding; Seattle Genetics: Honoraria; Pharmacyte: Honoraria; Pharmacyclics: Honoraria; Janssen: Honoraria; Pfizer: Honoraria; Medscape: Honoraria; Bayer: Honoraria; BMS: Honoraria, Research Funding; Sanofi: Honoraria.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH